The DOI matches its OpenAlex record; 85 of the 85 references it cites were found in a registry or an index.
Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies
Abstract
PURPOSE: Activation of the KIT tyrosine kinase by somatic mutation has been documented in a number of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis. In addition, paracrine or autocrine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer. In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies. MATERIALS AND METHODS: Studies were identified through a MEDLINE search, review of bibliographies of relevant articles, and review of abstracts from national meetings. RESULTS: Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia. The role of KIT inhibitors in treating KIT-positive malignancies is reviewed. CONCLUSION: Targeted therapy to inhibit the kinase activity of KIT is a rational approach to the treatment of KIT-positive malignancies. Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor. Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML. Additionally, KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationGain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationJoensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationMiettinen, M., & Lasota, J. (2001) · Virchows Archiv · doi:10.1007/s004280000338 · Cited by 1,854
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.
Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U., & Ullrich, A. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02655.x · Cited by 1,574
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationHuang, E., Nocka, K., Beier, D. R., Chu, T.-Y., Buck, J., Lahm, H.-W., Wellner, D., Leder, P., & Besmer, P. (1990) · Cell · doi:10.1016/0092-8674(90)90303-v · Cited by 1,155
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citationBuchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Self-citationWood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.
Sarlomo‐Rikala, M., Kovatich, A. J., Barusevicius, A., & Miettinen, M. (1998) · PubMed · Cited by 770
Hereditary Anemias of the Mouse: A Review for Geneticists
Russell, E. S. (1979) · Advances in Genetics · doi:10.1016/s0065-2660(08)60549-0 · Cited by 766
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., & Fletcher, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 642
Besmer, P., Murphy, J. E., George, P. C., Qiu, F., Bergold, P. J., Lederman, L., Snyder, H. W., Brodeur, D., Zuckerman, E. E., & Hardy, W. D. (1986) · Nature · doi:10.1038/320415a0 · Cited by 629
Prognosis of Gastrointestinal Smooth-Muscle (Stromal) Tumors: Dependence on Anatomic Site
Emory, T. S., Sobin, L. H., Lukes, L., Lee, D. H., & O'Leary, T. J. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199901000-00009 · Cited by 625
Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
Nishida, T., Hirota, S., Taniguchi, M., Hashimoto, K., Isozaki, K., Nakamura, H., Kanakura, Y., Tanaka, T., Takabayashi, A., Matsuda, H., et al. (1998) · Nature Genetics · doi:10.1038/1209 · Cited by 586
Longley, B. J., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 552
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Gonadal expression of c-kit encoded at the W locus of the mouse
Manova, K., Nocka, K., Besmer, P., & Bachvarova, R. F. (1990) · Development · doi:10.1242/dev.110.4.1057 · Cited by 484
Requirement for mast cell growth factor for primordial germ cell survival in culture
Dolci, S., Williams, D. E., Ernst, M. K., Resnick, J. L., Brannan, C. I., Lock, L. F., Lyman, S. D., Boswell, H. S., & Donovan, P. J. (1991) · Nature · doi:10.1038/352809a0 · Cited by 480
Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A., & Besmer, P. (1989) · Genes & Development · doi:10.1101/gad.3.6.816 · Cited by 474
Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors
谷口, 正. (2001) · Cited by 438
Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.459 · Cited by 429
Tsai, M., Takeishi, T., Thompson, H., Langley, K. E., Zsebo, K. M., Metcalfe, D. D., Geissler, E. N., & Galli, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6382 · Cited by 411
Activating c-kit Gene Mutations in Human Germ Cell Tumors
Tian, Q., Frierson, H. F., Krystal, G. W., & Moskaluk, C. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65419-3 · Cited by 408
Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.
Giebel, L. B., & Spritz, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8696 · Cited by 383
Blume-Jensen, P., Claesson-Welsh, L., Siegbahn, A., Zsebo, K. M., Westermark, B., & Heldin, C. H. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04989.x · Cited by 330
Blume-Jensen, P., Jiang, G., Hyman, R., Lee, K.-F., O'Gorman, S., & Hunter, T. (2000) · Nature Genetics · doi:10.1038/72814 · Cited by 315
C-kit mutations in core binding factor leukemias
Beghini, A., Peterlongo, P., Ripamonti, C. B., Larizza, L., Cairoli, R., Morra, E., & Mecucci, C. (2000) · Blood · doi:10.1182/blood.v95.2.726 · Cited by 299
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
Ikeda, H., Kanakura, Y., Tamaki, T., Kuriu, A., Kitayama, H., Ishikawa, J., Kanayama, Y., Yonezawa, T., Tarui, S., & Griffin, J. (1991) · Blood · doi:10.1182/blood.v78.11.2962.2962 · Cited by 280
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal, G. W., Honsawek, S., Litz, J., & Buchdunger, E. (2000) · PubMed · Cited by 265
c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia
Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I., & Reilly, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01449.x · Cited by 262
Kohn, D. B., Bauer, G., Rice, C. R., Rothschild, J. C., Carbonaro, D. A., Valdez, P., Hao, Q.-L., Zhou, C., Bahner, I., Kearns, K., et al. (1999) · Blood · doi:10.1182/blood.v94.1.368.413a47_368_371 · Cited by 258
Kitayama, H., Kanakura, Y., Furitsu, T., Tsujimura, T., Oritani, K., Ikeda, H., Sugahara, H., Mitsui, H., Kanayama, Y., & Kitamura, Y. (1995) · Blood · doi:10.1182/blood.v85.3.790.bloodjournal853790 · Cited by 233
Maeyama, H., Hidaka, E., Ota, H., Minami, S., Kajiyama, M., Kuraishi, A., Mori, H., Matsuda, Y., Wada, S., Sodeyama, H., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.20880 · Cited by 231
Mendel, D. B., Laird, A., Smolich, B. D., Blake, R., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., et al. (2000) · PubMed · Cited by 230
Chronic myeloid leukemia: current treatment options
Goldman, J. M., & Druker, B. J. (2001) · Blood · doi:10.1182/blood.v98.7.2039 · Cited by 224
Self-citationIsozaki, K., Terris, B., Belghiti, J., Schiffmann, S., Hirota, S., & Vanderwinden, J.-M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64795-5 · Cited by 223
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours
Hirota, S., Nishida, T., Isozaki, K., Taniguchi, M., Nakamura, J., Okazaki, T., & Kitamura, Y. (2001) · The Journal of Pathology · Cited by 221
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.
Natali, P. G., Nicotra, M., Sures, I., Santoro, E., Bigotti, A., & Ullrich, A. (1992) · PubMed · Cited by 218
Büttner, C., Henz, B. M., Welker, P., Sepp, N. T., & Grabbe, J. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00414.x · Cited by 209
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone, K., Belle, P. A. V., Elenitsas, R., & Elder, D. (1997) · PubMed · Cited by 206
Zermati, Y., De Sepulveda, P., Féger, F., Létard, S., Kersual, J., Castéran, N., Gorochov, G., Dy, M., Ribadeau Dumas, A., Dorgham, K., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206120 · Cited by 191
MEYTS, E. R., & SKAKKEBKK, N. E. (1994) · International Journal of Andrology · doi:10.1111/j.1365-2605.1994.tb01225.x · Cited by 181
Ingram, D. A., Yang, F.-C., Travers, J. B., Wenning, M. J., Hiatt, K., New, S., Hood, A., Shannon, K., Williams, D. A., & Clapp, D. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.181 · Cited by 181
Smolich, B. D., Yuen, H. A., West, K. A., Giles, F. J., Albitar, M., & Cherrington, J. M. (2001) · Blood · doi:10.1182/blood.v97.5.1413 · Cited by 180
Preferential expression of c-kit protooncogene transcripts in small cell lung cancer
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90235-c · Cited by 174
Beghini, A., Ripamonti, C. B., Peterlongo, P., Roversi, G., Cairoli, R., Morra, E., & Larizza, L. (2000) · Human Molecular Genetics · doi:10.1093/oxfordjournals.hmg.a018921 · Cited by 169
Sette, C., Dolci, S., Geremia, R., & Rossi, P. (2000) · The International Journal of Developmental Biology · doi:10.1387/ijdb.11061423 · Cited by 165
Gastrointestinal Stromal Tumors
(2017) · Springer eBooks · doi:10.1007/978-3-319-42632-7 · Cited by 164
Piao, X., Paulson, R., van der Geer, P., Pawson, T., & Bernstein, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14665 · Cited by 160
Packer, A. I., Besmer, P., & Bachvarova, R. F. (1995) · Molecular Reproduction and Development · doi:10.1002/mrd.1080420307 · Cited by 153
A new c‐kit mutation in a case of aggressive mast cell disease
Pignon, J., Giraudier, S., DUQUESNOY, P., Jouault, H., Imbert, M., Vainchenker, W., Vernant, J., & Tulliez, M. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2042.x · Cited by 153
A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor.
Lev, S., Givol, D., & Yarden, Y. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07993.x · Cited by 146
Ma, Y., Cunningham, M. E., Wang, X., Ghosh, I., Regan, L., & Longley, B. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13399 · Cited by 143
Coexpression of the c-kit and stem cell factor genes in breast carcinomas.
Hines, S. J., Organ, C. P., Kornstein, M. J., & Krystal, G. W. (1995) · PubMed · Cited by 142
Zhang, Q., Raghunath, P. N., Vonderheid, E. C., Ødum, N., & Wasik, M. A. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64629-9 · Cited by 142
Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group
Cohen, P., Chan, J., Lipkunskaya, M., Biedler, J. L., & Seeger, R. C. (1994) · Blood · doi:10.1182/blood.v84.10.3465.3465 · Cited by 138
Mesters, R. M., Padró, T., Bieker, R., Steins, M. B., Kreuter, M., Göner, M., Kelsey, S. M., Scigalla, P., Fiedler, W., Büchner, T., et al. (2001) · Blood · doi:10.1182/blood.v98.1.241 · Cited by 127
Druker, B. J. (1999) · Blood · Cited by 121
Self-citationBreast cancer is associated with loss of the c‐kit oncogene product
Natali, P. G., Nicotra, M., Sures, I., Mottolese, M., Botti, C., & Ullrich, A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520508 · Cited by 120
Chui, X., Egami, H., Yamashita, J., Kurizaki, T., Ohmachi, H., Yamamoto, S., & Ogawa, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.236 · Cited by 117
Ricotti, E., Fagioli, F., Garelli, E., Linari, C., Crescenzio, N., Horenstein, A. L., Pistamiglio, P., Vai, S., Berger, M., diMontezemolo, L. C., et al. (1998) · Blood · doi:10.1182/blood.v91.7.2397 · Cited by 108
Broudy, V., Smith, F. O., Lin, N., Zsebo, K. M., Egrie, J. C., & Bernstein, I. D. (1992) · Blood · doi:10.1182/blood.v80.1.60.60 · Cited by 108
Bokemeyer, C., Kuczyk, M. A., Dunn, T. A., Serth, J., Hartmann, K., Jonasson, J., Pietsch, T., Udo Jonas, A., & Schmoll, H. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01261407 · Cited by 99
Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., & Lipson, K. E. (2001) · PubMed · Cited by 97
Sekido, Y., Takahashi, T., Ueda, R., Takahashi, M., Suzuki, H., Nishida, K., Tsukamoto, T., Hida, T., Shimokata, K., & Zsebo, K. M. (1993) · PubMed · Cited by 92
Mauro, M. J., & Druker, B. J. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200101000-00002 · Cited by 84
Self-citationc-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi
Ohashi, A., Funasaka, Y., Ueda, M., & Ichihashi, M. (1996) · Melanoma Research · doi:10.1097/00008390-199602000-00004 · Cited by 84
Parrott, J. A., Kim, G., & Skinner, M. K. (2000) · Biology of Reproduction · doi:10.1095/biolreprod62.6.1600 · Cited by 84
Beghini, A., Cairoli, R., Morra, E., & Larizza, L. (1998) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.1998.0191 · Cited by 77
Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase
Moriyama, Y., Tsujimura, T., Hashimoto, K., Morimoto, M., Kitayama, H., Matsuzawa, Y., Kitamura, Y., & Kanakura, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3347 · Cited by 72
Ishikawa, K., Komuro, T., Hirota, S., & Kitamura, Y. (1997) · Cell and Tissue Research · doi:10.1007/s004410050859 · Cited by 71
Irusta, P. M., & DiMaio, D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.23.6912 · Cited by 69
Fleischman, R. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115772 · Cited by 69
Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains
Rousset, D., Agn�s, F., Lachaume, P., Andr�, C., & Galibert, F. (1995) · Journal of Molecular Evolution · doi:10.1007/bf00160313 · Cited by 63
Tsujimura, T., Hashimoto, K., Kitayama, H., Ikeda, H., Sugahara, H., Matsumura, I., Kaisho, T., Terada, N., Kitamura, Y., & Kanakura, Y. (1999) · Blood · doi:10.1182/blood.v93.4.1319 · Cited by 61
Lowry, P. A., Zsebo, K. M., Deacon, D., Ce, E., & Quesenberry, P. (1991) · PubMed · Cited by 61
Natkunam, Y., & Rouse, R. V. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200001000-00010 · Cited by 50
Beghini, A., Ripamonti, C. B., Castorina, P., Pezzetti, L., Doneda, L., Cairoli, R., Morra, E., & Larizza, L. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00221-6 · Cited by 44
Cole, S. R., Aylett, G. W., Harvey, N. L., Cambareri, A. C., & Ashman, L. (1996) · PubMed · Cited by 38
Sandlow, J. I., Feng, H. L., ZHENG, L. J., & Sandra, A. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)69003-9 · Cited by 24
Cited by
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Nilsson, B., Bümming, P., Meis‐Kindblom, J. M., Odén, A., Dortok, A., Gustavsson, B., Sablinska, K., & Kindblom, L. (2005) · Cancer · doi:10.1002/cncr.20862 · Cited by 1,272
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Gastrointestinal stromal tumour
Rubin, B. P., Heinrich, M. C., & Corless, C. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60780-6 · Cited by 1,036
Self-citation
Metadata
- Authors
- Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-03-15
- Volume
- 20
- Issue
- 6
- Pages
- 1692-1703
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2038596108
- Cited by
- 634
- References
- 85
- FWCI
- 49.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.